GSK Reports Q2 Beats and £1.9bn Cost Savings Plan to 2029
GSK posted Q2 revenue and core operating profit above consensus and outlined a £1.9bn cost-savings programme through 2029, lifting its mid-term margin outlook. Reported operating profit fell 75% and EPS dropped 69%, largely due to a £1.33bn impairment tied to camlipixant and higher legal charges. Analyst 12-month price targets varied widely, with the next results due 28 October 2026.